放射性配体靶向前列腺特异性膜抗原在前列腺外疾病中的应用:现状与未来展望
本文综述了前列腺特异性膜抗原(PSMA)在前列腺癌以外疾病中的表达及放射性配体靶向应用的临床研究现状,指出PSMA在非前列腺肿瘤中主要表达于肿瘤相关新生血管内皮细胞,并基于组织病理学检查探讨了其在非前列腺恶性肿瘤分期、分子表征及PSMA靶向放射性核素治疗中的未来前景。
要点
- PSMA在生理组织及良恶性疾病中均有非前列腺相关表达,非前列腺肿瘤细胞中仅罕见观察到PSMA表达。
- 非前列腺肿瘤中PSMA表达发生于肿瘤相关新生血管内皮细胞,生理条件下未见内皮表达。
- 首批患者研究已证实PSMA用于非前列腺恶性肿瘤分期的潜力,本综述据此归纳未来方向。
核心结论
- PSMA并非前列腺癌所独有,这为利用现有放射性PSMA配体对非前列腺疾病进行显像、分子表征乃至治疗提供了可能。
研究设计与样本
- 本文为综述,汇总首批临床研究,并基于PSMA表达的组织病理学检查推导未来展望。
主要发现
- 非前列腺肿瘤细胞中仅罕见观察到PSMA表达,表达主要见于肿瘤相关新生血管内皮细胞。
- 生理条件下未观察到内皮PSMA表达,而生理组织及良恶性疾病中均有非前列腺相关PSMA表达报道。
- 首批患者研究已证实PSMA用于非前列腺恶性肿瘤分期的潜力。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific membrane antigen (PSMA) is the up-and-coming target for molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA expression in physiologic tissue as well as in benign and malignant disease has been reported in various publications. Unlike in prostate cancer, PSMA expression is only rarely observed in non-prostate tumor cells. Instead, expression occurs in endothelial cells of tumor-associated neovasculature, although no endothelial expression is observed under physiologic conditions. The resulting potential for tumor staging in non-prostate malignant tumors has been demonstrated in first patient studies. This review summarizes the first clinical studies and deduces future perspectives in staging, molecular characterization, and PSMA-targeted radionuclide therapy based on histopathologic examinations of PSMA expression. CONCLUSIONS: The non-exclusivity of PSMA in prostate cancer opens a window to utilize the spectrum of available radioactive PSMA ligands for imaging and molecular characterization and maybe even therapy of non-prostate disease.
引用
- Backhaus P, Noto B, Avramovic N, et al. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur J Nucl Med Mol Imaging. 2018. PMID: 29335762. doi:10.1007/s00259-017-3922-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。